Design Therapeutics Stock In The News
| DSGN Stock | USD 4.71 0.01 0.21% |
Our overall analysis of Design Therapeutics' news coverage and content from conventional and social sources shows investors' bearish mood towards Design Therapeutics. The specific impact of Design Therapeutics news on its stock price will depend on a range of factors, including the nature and significance of the news report and investors' perceptions of Design Therapeutics' overall financial health and prospects. It also depends on the type and quality of a news publisher.
Some academic researchers believe in a strong correlation between financial news and their impacts on the movements of stock prices. Macroaxis does not take a position on this subject and only provides tools that can help investors to time the market using Design Therapeutics headlines in addition to utilizing other, more conventional financial analysis modules. Check out Design Therapeutics Backtesting and Design Therapeutics Hype Analysis. To learn how to invest in Design Stock, please use our How to Invest in Design Therapeutics guide.
Design |
Design Therapeutics Today Top News and Investor Outlook
Design Therapeutics Past News Timeline
Popular news outlets such as MarketWatch, Bloomberg, or Reuters provide Design and other traded companies coverage with news coverage. We help investors stay connected with Design headlines for the 16th of March 2025 to make an informed investment decision based on correlating the impacts of news items on Design Stock performance. Please note that trading solely based on the Design Therapeutics hype is not for everyone as timely availability and quick action are needed to avoid losses.
Design Therapeutics stock price changes are notoriously difficult to predict based exclusively on its news coverage or social hype. Still, the Design earnings-per-share ratio is a good starting point for gauging a company's future prospects. If a firm's EPS rises and meets or even beats consensus forecasts, its shares stand to increase. However, some very sophisticated investors can spot management manipulation of EPS through actions such as buybacks.
Far too much social signal, news, headlines, and media speculation about Design Therapeutics that are available to investors today. That information is available publicly through Design media outlets and privately through word of mouth or via Design internal channels. However, regardless of the origin, that massive amount of Design data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Design Therapeutics news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Design Therapeutics relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Design Therapeutics' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Design Therapeutics alpha.
Design Largest EPS Surprises
Earnings surprises can significantly impact Design Therapeutics' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2025-03-17 | 2024-12-31 | -0.2667 | -0.24 | 0.0267 | 10 | ||
2022-11-03 | 2022-09-30 | -0.29 | -0.32 | -0.03 | 10 | ||
2022-03-10 | 2021-12-31 | -0.23 | -0.2 | 0.03 | 13 | ||
2023-08-14 | 2023-06-30 | -0.4 | -0.36 | 0.04 | 10 | ||
2021-08-09 | 2021-06-30 | -0.18 | -0.14 | 0.04 | 22 | ||
2024-05-08 | 2024-03-31 | -0.26 | -0.2 | 0.06 | 23 |
Design Therapeutics Stock Latest Headlines
Some academic researchers believe in a strong correlation between financial news and their impacts on the movements of stock prices. Macroaxis does not take a position on this subject and only provides tools that can help investors to time the market using conventional financial analysis. Below is the latest headlines and news related to Design Therapeutics Stock. Current markets are strongly bullish. About 93% of major world exchanges and indexes are currently up. See today's market update for more information.
13th of March 2025
Disposition of 814874 shares by William Arsani of Design Therapeutics at 4.25 subject to R... at MacroaxisInsider
12th of March 2025
Acquisition by Pratik Shah of 415000 shares of Design Therapeutics at 7.97 subject to Rule... at zacks.com
10th of March 2025
Design Therapeutics Highlights Progress Across Lead GeneTAC Pro at gurufocus.com
3rd of March 2025
Design Therapeutics to Participate in Leerinks Global Healthcare Conference at globenewswire.com
19th of February 2025
US Penny Stocks To Watch In February 2025 - Simply Wall St at news.google.com
12th of February 2025
Acquisition by George Simeon of 15000 shares of Design Therapeutics subject to Rule 16b-3 at MacroaxisInsider
4th of February 2025
Short Interest in Design Therapeutics, Inc. Increases By 8.1 at thelincolnianonline.com
13th of January 2025
Astria Therapeutics Announces Design of ALPHA-ORBIT Pivotal Phase 3 Trial of Navenibart in... at news.google.com
16th of December 2024
Design Therapeutics SWOT analysis geneTAC stock faces early-stage hurdles at investing.com
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Design Therapeutics in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Design Therapeutics' short interest history, or implied volatility extrapolated from Design Therapeutics options trading.
Check out Design Therapeutics Backtesting and Design Therapeutics Hype Analysis. To learn how to invest in Design Stock, please use our How to Invest in Design Therapeutics guide.You can also try the ETFs module to find actively traded Exchange Traded Funds (ETF) from around the world.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Design Therapeutics. If investors know Design will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Design Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Design Therapeutics is measured differently than its book value, which is the value of Design that is recorded on the company's balance sheet. Investors also form their own opinion of Design Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Design Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Design Therapeutics' market value can be influenced by many factors that don't directly affect Design Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Design Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Design Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Design Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.